Grants & Sponsorships
Phathom Pharmaceuticals is currently evaluating vonoprazan* (potassium-competitive acid blocker) vs active comparator lansoprazole (protein-pump inhibitor)
Accessibility Statement
We are currently working to increase the accessibility and usability of our website so as to adhere to many of the available standards and guidelines.
Medical Information
Phathom Pharmaceuticals is working to change the GI treatment landscape and improve the lives of patients with acid-related disorders.
Publications & Scientific Congresses
A complete listing of related publications.
Phathom Pharmaceuticals Announces Leadership Succession Plan and Strengthens Board of Directors with New Appointments
Terrie Curran, President, Global Inflammation and Immunology Franchise at Celgene Corporation, to succeed David Socks as CEO Michael Cola, Terrie Curran, Heidi Kunz, and Chris Slavinsky appointed to Board of Directors BUFFALO GROVE, ILLINOIS, September 27, 2019 – Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on the...
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020 FLORHAM PARK, NJ.–Feb. 25, 2020– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief Executive...